The kinetics of humoral response and its relationship with the disease severity in COVID-19
Ren L, Zhang L, Chang D, Wang J, Hu Y, Chen H, Guo L, Wu C, Wang C, Wang Y, Wang Y, Wang G, Yang S, Dela Cruz CS, Sharma L, Wang L, Zhang D, Wang J. The kinetics of humoral response and its relationship with the disease severity in COVID-19. Communications Biology 2020, 3: 780. PMID: 33311543, PMCID: PMC7733479, DOI: 10.1038/s42003-020-01526-8.Peer-Reviewed Original ResearchConceptsHumoral responseDisease severityReceptor-binding domainAntibody titersSpike proteinSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2COVID-19Respiratory syndrome coronavirus 2Titers of NAbsGeometric mean titersCOVID-19 patientsSyndrome coronavirus 2Coronavirus disease 2019Disease courseMean titersCoronavirus 2Antibody responseIgG antibodiesRisk factorsIg levelsImmunoglobulin ADisease 2019Severe casesModerate infectionsSevere respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia
Gautam S, Cohen AJ, Stahl Y, Toro P, Young GM, Datta R, Yan X, Ristic NT, Bermejo SD, Sharma L, Restrepo M, Dela Cruz CS. Severe respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia. Thorax 2020, 75: 974-981. PMID: 32826284, DOI: 10.1136/thoraxjnl-2020-214896.Peer-Reviewed Original ResearchConceptsPure viral infectionBacterial coinfectionViral infectionInfluenza infectionSevere respiratory viral infectionsAbility of procalcitoninRetrospective cohort studyViral respiratory infectionsRespiratory viral infectionsMarker of severityRespiratory viral illnessSevere viral infectionsSpecificity of procalcitoninCharacteristic curve analysisCellular modelHigher procalcitoninProcalcitonin expressionElevated procalcitoninCohort studyViral illnessRespiratory infectionsAntibiotic administrationBacterial pneumoniaSevere diseaseProcalcitoninPersistent Viral Presence Determines the Clinical Course of the Disease in COVID-19
Chang D, Zhao P, Zhang D, Dong JH, Xu Z, Yang G, Li BY, Liu HX, Li BA, Qin CF, Peng XH, Wang FS, Xie LX, Chen Z, Dela Cruz CS, Sharma L, Qin EQ. Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 2585-2591.e1. PMID: 32574840, PMCID: PMC7305869, DOI: 10.1016/j.jaip.2020.06.015.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBetacoronavirusC-Reactive ProteinChildChild, PreschoolComorbidityCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHumansInfantInflammationInflammation MediatorsInterleukin-6MaleMiddle AgedPandemicsPneumonia, ViralReal-Time Polymerase Chain ReactionRespiration, ArtificialSARS-CoV-2Severity of Illness IndexYoung AdultConceptsDisease severityViral clearanceViral persistenceDisease outcomeCOVID-19Viral presenceExtensive lung involvementC-reactive proteinEffective antiviral therapyCoronavirus disease 2019Severe disease outcomesHost antiviral mechanismsInfectious viral particlesImmunomodulatory therapyInflammatory markersLung involvementRespiratory supportClinical courseAntiviral therapyIL-6Viral reactivationClinical managementInflammatory responseChest imagingDisease 2019